Xogta Wejiga III ee ku taal daroogada cusub ee Shiinaha ee Shiinaha ee CREST ee NEJM Show Efficiccy kama liidato Paxlovid

Saacadaha hore ee 29kii Disembar, Nejm waxaa lagu daabacay khadka tooska ah ee Wajiga cusub ee Centelinta ee III Daraasad ku saabsan Cusub Coronavirus-ka cusub ee Shiinaha VV116. Natiijooyinka ayaa muujinaya in VV116 uusan ka xumaanin Paxlovid (Nematoviir / Ritononavir) marka loo eego muddada ka soo kabashada kiliinikada oo ay ka yaraatay dhacdooyin xun.

Image Isha Ima Iska Isugeynta: nejm

Waqtiga soo kabashada ee 4-da maalmood, qiimeynta dhacdada 57.4%

VV116 waa afka nucleurus afka ah ee maskaxda (SARS-Corofan-2)) daroogada (SARS-MEOV-2) ee ay lashaqeeyaan Junsit iyo Wang Shan Wang Shui, oo ay ku jiraan MOLKIVICS MOLNuPiraviir iyo Dohme ee Molnupudine.

Sannadkii 2021, marxaladda caafimaad ee farxanka ah ee Marxaladda II ee VV116 ayaa lagu dhammeeyay Uzbekistan. Natiijooyinka daraasadda ayaa muujisay in kooxda VV116 ay sifiican u wanaajin karto astaamaha caafimaad waxayna si weyn u yareyn karaan halista horumarka qaabka muhiimka ah iyo geeri lala yeesho kooxda kantaroolka. Iyada oo ku saleysan natiijooyinka wanaagsan ee maxkamaddan, VV116 ayaa lagu ansixiyay Uzbekistan si loogu daweeyo bukaannada qaba bokh-daran-19, waxayna noqotay dawada ugu horeysa ee loo yaqaan 'Coronary Coronary-ka' ee dibedda loogu oggolaaday dibada Shiinaha ee Shiinaha [1].

MARKA MARKA III CUTISTIAL OCTIALITH [2] (NCT03341609), oo ay hogaaminayeen Prof. Zhao Reng oo ka mid ah Shanghai Ruijins Hospital, oo uu sababay muddadii ay ka dhasheen shismada (B.1.529) ilaa Maarso ilaa bisha May ee Shanghai, iyadoo ujeedkiisu yahay Shanghai. Qiimaynta wax ku oolka iyo badbaadada VV116 Paxlovid ee paxlovid ee loogu talagalay daaweynta hore ee bukaannada qaba bovid-ka dhexdhexaad ah-19. Ujeeddadu waxay ahayd in la qiimeeyo wax ku oolka iyo badbaadada VV116 vaxlovid ee paxlovid ee loogu talagalay daaweynta bukaan hore ee bukaan-socodka iyo dhexdhexaad-19.

Isha sawirka: Tixraaca 2

Multiretre, indho-indheyn, oo la kala soocay, oo la xakameeyay, maxkamad la xakameeyay oo ah 822 bukaan oo ah bukaan-naqab-weyn oo halis ah oo lagu sameeyo inta u dhaxaysa 4-ta Abriil iyo 2-da May 2022 ee Shanghai, Shiinaha. Ugu dambeyntiina, 771 kaqeybgalayaashu waxay heleen midkood VV116 (384, 600 mg 12-ka saac ee maalintii 1-5 mg Nimatuvir + 100 mg nimatuvir + 100 mg ritonavir 12-ka saacadood ee ah 5-da maalmood) daawo ahaan.

Natiijooyinka daraasaddan rugta caafimaad waxay muujisay in daaweynta hore ee VV116 ee loo yaqaan 'Chional Covid-19' oo ay ku sii wadaysaa ka soo kabashada rugta caafimaadka ah) oo saadaalineysa zactorol-ka PaxLolo, 1.02; 95.

Joogtaynta waqtiga soo kabashada

Xeerka aasaasiga iyo sare ee waxtarka leh (falanqaynta dhameystiran ee dadka)

Isha sawirka: Tixraaca 2

Marka laga hadlayo nabadgelyada, kaqeybgalayaashu waxay ka warbixiyeen VV116 oo ay sheegeen inay ka yar yihiin dhacdooyinka ka yar (67.4%) ee dabagalka Paxlovid (77%), iyo in dhacdada 'FAST-ka' ay ka hooseeyeen VV116 (2.6%) marka loo eego Paxlovid (5.7%).

Dhacdooyinka xun (dadka aaminka ah)

Isha sawirka: Tixraaca 2

Muhiimadaha iyo su'aalaha

Bishii Meey 23, 2022, juper ayaa shaaca ka qaaday in Webiper-ka uu shaaca ka qaaday in Wejiga III Daraasad caafimaad ee VV116 Paxlovid ee VOVID-da-ka si dhexdhexaad ah-19 (NCT033411609) ayaa la kulmay xafladdiisa waxbarasho ee aasaasiga ah.

Isha sawirka: Tixraaca 1

Waqti markii ay faahfaahinta maxkamadda ka maqnaato, muranka ku saabsan Daraasadda Wajiga III: Marka hore, waxay ka baqday indhoole, oo ay adkaan laheyd inay sifiican u xukunto daroogada. Marka labaad, waxaa jiray su'aalo ku saabsan xafladaha caafimaad.

Shuruudaha ku-darista ee kiliinikada ee Junsure waa (i) Natiijooyinka wanaagsan ee baaritaanka cusub, (ii) hal ama in ka badan astaamo-weyn-qafiif ah ama dhexdhexaad ah, iyo (iii) bukaannada halista ugu badan ee qatar-xumo-19, oo ay kujiraan dhimashada. Si kastaba ha noqotee, xafladda kaliya ee ugu caansan ee xarunta caafimaad ee koowaad waa 'waqtiga la sii waday bogsiinta caafimaad ee'.

Ku dhawaaqida kahor, May 14, Juniper wuxuu dib u eegay xafladaha caafimaad iyadoo laga saarayo mid ka mid ah xafladaha aasaasiga ah ee caafimaadka, "saamiga isugeynta bukaan-socodka ama dhimashada" [3].

Isha sawirka: Tixraaca 1

Labadan qodob ee ugu muhiimsan ee khilaafku sidoo kale si gaar ah looga hadlay daraasadda la daabacay.

Sababo la xiriira faafitaanka lama filaanka ah ee digicron, soosaarka kiniiniyada loo yaqaan 'platbo kiniiniyada paxlovid' ee paxlovid ah lama dhammaystirin ka hor bilowga maxkamadda sidaas darteedna ma aysan awoodin inay ku sameeyaan tijaabadan iyagoo adeegsanaya labanlaab laba-indhoole ah. Marka loo eego qaybta hal-indha la 'ee tijaabada caafimaad, juper wuxuu sheegay in borotokoolka lagu sameeyay ka dib markii la xiriirta mas'uuliyiintu ay ka mid tahay is-beddelka ay garaneyso qoondaynta daweynta ee gaarka ah ilaa macluumaadka ugu dambeeya la xirayo dhamaadka daraasadda.

Ilaa waqtiga falanqaynta kama dambaysta ah, midkoodna kaqeybgalayaasha maxkamada ay la kulmeen geerida ama horumarka dhacdo culus - si ay u gunaanado ku saabsan VV116 si looga hortago horumarka VV116 si looga hortago samaynta si daran ama muhiim ah - 19 ama dhimasho. Xogta ayaa muujisay in waqtiga dhexe ee laga qiyaasey si aan kala sooc lahayn oo ah dib-u-haynta calaamadaha joogtada ah ee bartilmaameedka ah ee ahaa 7 maalmood (saamiga halista ah, 1.05% CI, boqolkiiba 95). Ma ahan wax adag in la sharaxo sababta loogu talagalay 'heerka koowaad ee' heerka ugu beddelashada 'jirro daran ama dhimasho', kaas oo markii hore loo dejiyey ka hor dhamaadka tijaabada, laga saaray.

18-ka Meey 2022, joornaalka microbes-ka oo soo baxaya iyo infekshannada soo ifbaxaya ayaa lagu daabacay natiijooyinka tijaabooyinka caafimaad ee ugu horreeyay ee VV116 ee bukaanka qaba cudurka omiceron-ka [4], waxbarasho isku-dhafan, oo ay ku dhameeyaan ardayda bukaan-jiifka ah.

Xogta daraasadda daraasaddu waxay muujisay in bukaannada qaba cudurka cudurka oticeron ee adeegsaday VV116 5 maalmood gudahood laga bilaabo imtixaankoodii ugu horreeyay ee Nucleic acid ee Nucleic ay haysteen 8.56 maalmood, in ka yar 11.13 maalmood oo ka mid ah kooxda koontaroolka. Maamulka VV116 ee bukaanka astaanta ku jira waqtiga loo yaqaan 'Waqtiga' Daraasaddan '(2-10 maalmood ee imtixaanka hore ee cudurka Nucleic acid) ayaa hoos u dhigay waqtiga ka jawaabista asiidhka ee dhammaan bukaanada. Marka laga hadlayo badbaadada daroogada, dhib xun xun looma arko kooxda daaweynta ee VV116.

Isha sawirka: Tixraaca 4

Waxaa jira seddex tijaabooyin caafimaad oo degel ah oo ku saabsan VV116, oo labo ka mid ah ay yihiin wejiga Marxaladda III ee ku saabsan Daraasadaha Cilmiga fudud ilaa dhexdhexaad-19 (NCT05242042, NCT05582629). Maxkamada kale ee loo yaqaan 'Covid' oo dhexdhexaad ah ilaa dhexdhexaad-19 waa mid caalami ah, wajiga, wejiga indhoolaha, wejiga indhoolaha III daraasad caafimaad (NCT05279233) si loo qiimeeyo waxtarka iyo badbaadada VV116 marka loo barbar dhigo daaweynta caadiga ah. Sida ku xusan ogeysiiska ee Junsuriyada, bukaanka koowaad ayaa la qoray oo la qabtay bishii Maarso 2022.

Image Isha Ima Iska Isugeynta: Rugaha Caafimaadka.gov

Tixraacyada:

[1] Junshi Biotech: Ogeysiis ku saabsan meesha ugu dambeysa ee dhamaadka Wajiga ee III ee diiwaangashan caafimaad ee rugta caafimaad ee VV116 Paxlovid ee Paxlovid si loogu daaweeyo sifooyin dhexdhexaad ah ilaa dhexdhexaad-19

[2] https://www.nejm.org/doi/dojml/10.106/NEJMMOA220882?Qaars_ 3] Httpstrials.gov/chow/record/Nct0534160] Ensi/Si, Jingwen Ai, Yi Zhang, Jaining Zodeng Gaoo, JunMing Xu, Hamiring Xu, hao yin, zhiren fu, hao ', Li Ly, L Lv, Ling Chen, Rooyue zhu, zhijun Zhang, zhengxin Wang. (2022) Infekshannada Cunton iyo xaalada tallaalka ee ka mid ah 1881 qaataha beerka ee beerka: isku-darka dib-u-eegida-ka-hortagga. Micybes & caabuqyada 11: 1, bogagga 2636-2644.